A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
← catalyst calendarNCT06602479 · readout in 121 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Prevention
Enrollment
488estimated
Sites
54
Countries
Czechia, Denmark, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-07 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: MEDI0618
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFEfficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine
measured Week 9 to Week 12
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed